Francisco Beca1, Rosario Andre2, Duarte Saraiva Martins3, Tiago Bilhim4, Diana Martins5, Fernando Schmitt6. 1. Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, USA IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal Faculty of Medicine, Department of Pathology and Oncology, University of Porto, Porto, Portugal. 2. Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal Department of Genetics, Oncology and Human Toxicology, Faculdade de Ciencias Medicas, Universidade Nova de Lisboa, Lisbon, Portugal. 3. Department of Pediatric Cardiology, Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal. 4. Department of Radiology, Faculdade de Ciências Médicas, Universidade Nova de Lisboa and Hospital de São José, Centro Hospitalar de Lisboa Central, Lisbon, Portugal. 5. IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal. 6. IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal Faculty of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada Department of Pathology, University Health Network, Toronto, Canada.
Abstract
AIMS: Despite considerable interest in the PI3K/AKT/mTOR pathway in breast carcinomas (BC), published data reports contradictory results regarding the association of phosphorylated mammalian target of Rapamycin (p-mTOR) expression with clinico-pathological features and prognosis in BC. Here, we evaluate the main clinico-pathological associations with p-mTOR expression in BC, with focus on the different molecular subtypes. METHODS: In this retrospective study, 331 BC patients were included in final analysis. Outcome measures included disease-free survival (DFS) and overall survival (OS) times. Baseline data and outcome measures were compared between immunohistochemical p-mTOR expressing and non-expressing BCs. Subgroup analysis was performed to assess the effect of p-mTOR expression in the outcome for each BC molecular subtype. RESULTS: 43.8% of the tumours were positive for p-mTOR, with a significant correlation between p-mTOR expression with smaller (<2 cm) (p=0.021) and lower-grade tumours (p<0.001). Expression of p-mTOR was also associated with longer DFS (HR of 0.32, p<0.001) and OS (HR of 0.20, p<0.001). In a multivariable analysis, the HR remained significant with minimal change (HR=0.26, p=0.002 for OS; HR=0.40, p=0.002 for DFS). In subgroup analysis, luminal p-mTOR-expressing tumours demonstrated longer DFS and OS (HR 0.33, p=0.003; HR 0.20, p=0.003, respectively) independently of size, grade, lymph node status and Her-2 overexpression. CONCLUSIONS: p-mTOR expression is associated with smaller, lower-grade and with luminal BC. In multivariable analysis, p-mTOR expression was associated with longer DFS and OS, independently of the size, grade and lymph node status, especially in luminal BCs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: Despite considerable interest in the PI3K/AKT/mTOR pathway in breast carcinomas (BC), published data reports contradictory results regarding the association of phosphorylated mammalian target of Rapamycin (p-mTOR) expression with clinico-pathological features and prognosis in BC. Here, we evaluate the main clinico-pathological associations with p-mTOR expression in BC, with focus on the different molecular subtypes. METHODS: In this retrospective study, 331 BC patients were included in final analysis. Outcome measures included disease-free survival (DFS) and overall survival (OS) times. Baseline data and outcome measures were compared between immunohistochemical p-mTOR expressing and non-expressing BCs. Subgroup analysis was performed to assess the effect of p-mTOR expression in the outcome for each BC molecular subtype. RESULTS: 43.8% of the tumours were positive for p-mTOR, with a significant correlation between p-mTOR expression with smaller (<2 cm) (p=0.021) and lower-grade tumours (p<0.001). Expression of p-mTOR was also associated with longer DFS (HR of 0.32, p<0.001) and OS (HR of 0.20, p<0.001). In a multivariable analysis, the HR remained significant with minimal change (HR=0.26, p=0.002 for OS; HR=0.40, p=0.002 for DFS). In subgroup analysis, luminal p-mTOR-expressing tumours demonstrated longer DFS and OS (HR 0.33, p=0.003; HR 0.20, p=0.003, respectively) independently of size, grade, lymph node status and Her-2 overexpression. CONCLUSIONS: p-mTOR expression is associated with smaller, lower-grade and with luminal BC. In multivariable analysis, p-mTOR expression was associated with longer DFS and OS, independently of the size, grade and lymph node status, especially in luminal BCs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
BREAST CANCER; BREAST PATHOLOGY; SURGICAL PATHOLOGY
Authors: Darío García-Carracedo; Maria Ángeles Villaronga; Saúl Álvarez-Teijeiro; Francisco Hermida-Prado; Iñigo Santamaría; Eva Allonca; Laura Suárez-Fernández; Maria Victoria Gonzalez; Milagros Balbín; Aurora Astudillo; Pablo Martínez-Camblor; Gloria H Su; Juan Pablo Rodrigo; Juana María García-Pedrero Journal: Oncotarget Date: 2016-05-17
Authors: Ting-Yuan David Cheng; Angela R Omilian; Song Yao; Pamela V Sanchez; Latasia Z Polk; Weizhou Zhang; Susmita Datta; Wiam Bshara; Rochelle Payne Ondracek; Warren Davis; Song Liu; Chi-Chen Hong; Elisa V Bandera; Thaer Khoury; Christine B Ambrosone Journal: NPJ Breast Cancer Date: 2020-09-21